Constellation Energy Corporation vs ClearPoint Neuro Inc — how do they compare? Constellation Energy Corporation trades at $261.15 (market cap $91.57B), while ClearPoint Neuro Inc trades at $15.92 (market cap $478.63M). The key difference: Constellation Energy Corporation is far larger — about 191.3× ClearPoint Neuro Inc's market cap, and Constellation Energy Corporation pays a 0.67% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CEG | CLPT | |
|---|---|---|
Market Cap | $91.57B | $478.63M |
Sector | Energy | Health |
52-Week High | $403.95 | $29.60 |
52-Week Low | $236.50 | $8.66 |
Enterprise Value | $113.24B | $506.63M |
Dividend Yield | 0.67% | — |
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.
The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Trailing returns across standard periods
Latest headlines on both assets
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →